Newsletter
Newsletter July 2020
We are currently experiencing technical problems with our electronical distribution of newsletters I am delighted to present my first newsletter as CEO for Cyxone. The first month in the company has been intense, exciting and interesting. I am busy...
Read MoreNewsletter December 2019
Read in web browser CEO comments The recent past has been very eventful. Important intermediary goals have been achieved in the development processes of both Rabeximod and T20K. Much is ongoing within the organization and we are in the...
Read MoreNewsletter November 2019
Read in web browser CEO comments As the days get shorter and the darkness falls earlier and earlier for each day, I am very happy about the many good news that has come to characterize Cyxone lately, which is...
Read MoreNewsletter September 2019
Read in web browser CEO comments During the recent months, we have been able to communicate milestones that we, together with our collaboration partners, have worked hard to fulfill. Both T20K and Rabeximod have during summer taken strong steps...
Read MoreNewsletter June 2019
Read in web browser CEO comments At last, it has finally become time to resume communication with your shareholders via newsletters. Cyxone has kept a low profile while we prepared for our clinical studies and now, when we have...
Read MoreNewsletter July 2018
There are many who show great interest for Cyxone and our drug candidates. We are pleased about the discussions happening around the effects of T20K and Rabeximod and what it can lead to in the future. Since there seems...
Read MoreNewsletter April 2018
We are right in the middle of an exciting period for Cyxone with a lot of moving pieces and I get a lot of questions from shareholders that I would like to answer, but I am not always able...
Read MoreNewsletter February 2018
I once read a comment from a Cyxone shareholder that said the less the company communicates, the more we are getting done. With this newsletter, I want to prove that statement accurate! In recent months, Cyxone has focused on...
Read MoreNewsletter January 2018
CEO’s comments 2017 was an exceptional year for Cyxone. In addition to running our original project – T20K for multiple sclerosis – we made progress in obtaining a clinical license for Rabeximod, a treatment for rheumatoid arthritis, for which...
Read MoreNewsletter 1 December 2017
Extraordinary General Meeting and new directed share issue to take Rabeximod through Phase 2B trials Prior to the extraordinary general meeting (EGM) that will be held in Malmö on December 11, at 10AM, I would first like to thank...
Read More